RU2016110546A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016110546A3 RU2016110546A3 RU2016110546A RU2016110546A RU2016110546A3 RU 2016110546 A3 RU2016110546 A3 RU 2016110546A3 RU 2016110546 A RU2016110546 A RU 2016110546A RU 2016110546 A RU2016110546 A RU 2016110546A RU 2016110546 A3 RU2016110546 A3 RU 2016110546A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361879895P | 2013-09-19 | 2013-09-19 | |
| US61/879,895 | 2013-09-19 | ||
| PCT/US2014/055816 WO2015042029A1 (en) | 2013-09-19 | 2014-09-16 | Combination drug therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016110546A RU2016110546A (ru) | 2017-10-24 |
| RU2016110546A3 true RU2016110546A3 (enExample) | 2018-03-20 |
Family
ID=52689320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016110546A RU2016110546A (ru) | 2013-09-19 | 2014-09-16 | Комбинированная лекарственная терапия |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160228446A1 (enExample) |
| EP (1) | EP3046556A4 (enExample) |
| JP (3) | JP6346944B2 (enExample) |
| KR (1) | KR20160055911A (enExample) |
| CN (1) | CN105530934A (enExample) |
| AU (1) | AU2014321456B2 (enExample) |
| BR (1) | BR112016005000A8 (enExample) |
| CA (1) | CA2921156A1 (enExample) |
| RU (1) | RU2016110546A (enExample) |
| WO (1) | WO2015042029A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6346944B2 (ja) * | 2013-09-19 | 2018-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組み合わせ薬物療法 |
| US10206949B2 (en) | 2015-09-21 | 2019-02-19 | Ofer Agam | Composition that relieves heartburn, GERD and hangovers |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US20210393651A1 (en) * | 2018-11-09 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| AU2007212447B2 (en) * | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
| BRPI0709771B1 (pt) * | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| RU2554081C2 (ru) * | 2010-02-24 | 2015-06-27 | Медивэйшн Простейт Терапьютикс, Инк. | Способ синтеза соединений диарилтиогидантоина и диарилгидантоина |
| KR101594002B1 (ko) * | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
| US20150342957A1 (en) * | 2013-01-09 | 2015-12-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination |
| EP2945628B1 (en) * | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| JP6346944B2 (ja) * | 2013-09-19 | 2018-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組み合わせ薬物療法 |
-
2014
- 2014-09-16 JP JP2016515414A patent/JP6346944B2/ja not_active Expired - Fee Related
- 2014-09-16 CN CN201480051583.9A patent/CN105530934A/zh active Pending
- 2014-09-16 BR BR112016005000A patent/BR112016005000A8/pt not_active IP Right Cessation
- 2014-09-16 EP EP14846138.7A patent/EP3046556A4/en not_active Withdrawn
- 2014-09-16 AU AU2014321456A patent/AU2014321456B2/en not_active Ceased
- 2014-09-16 KR KR1020167009965A patent/KR20160055911A/ko not_active Ceased
- 2014-09-16 US US15/022,561 patent/US20160228446A1/en not_active Abandoned
- 2014-09-16 CA CA2921156A patent/CA2921156A1/en not_active Abandoned
- 2014-09-16 RU RU2016110546A patent/RU2016110546A/ru not_active Application Discontinuation
- 2014-09-16 WO PCT/US2014/055816 patent/WO2015042029A1/en not_active Ceased
-
2018
- 2018-05-28 JP JP2018101120A patent/JP6563558B2/ja not_active Expired - Fee Related
-
2019
- 2019-07-24 JP JP2019135772A patent/JP2019196391A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6563558B2 (ja) | 2019-08-21 |
| AU2014321456A1 (en) | 2016-03-10 |
| CN105530934A (zh) | 2016-04-27 |
| AU2014321456B2 (en) | 2018-05-24 |
| RU2016110546A (ru) | 2017-10-24 |
| WO2015042029A1 (en) | 2015-03-26 |
| JP6346944B2 (ja) | 2018-06-20 |
| JP2019196391A (ja) | 2019-11-14 |
| JP2016530208A (ja) | 2016-09-29 |
| US20160228446A1 (en) | 2016-08-11 |
| EP3046556A4 (en) | 2017-04-26 |
| CA2921156A1 (en) | 2015-03-26 |
| BR112016005000A8 (pt) | 2018-01-23 |
| KR20160055911A (ko) | 2016-05-18 |
| EP3046556A1 (en) | 2016-07-27 |
| JP2018158930A (ja) | 2018-10-11 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190926 |